Skip to Main Content

INFORMATION FOR

    Diseases of the Digestive System - Liver, Phase II

    Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

    What is the purpose of this trial?

    This research study is for people who may have abnormally high amount of fat and swelling (inflammation) of their liver along with some fibrosis (scarring) that is not related to excessive alcohol consumption. The medical term for this condition is nonalcoholic steatohepatitis (NASH) that has both high liver fat and inflammation (swelling) and fibrosis (scarring) that causes a stiff liver. This research study involves two investigational drugs (study drugs) as potential options to treat patients with NASH with liver fibrosis.

    • Trial with
      Pfizer Inc., U.S. Pharmaceuticals Group
    • Ages
      18 years - 75 years
    • Gender
      Both

    Contact Information

    For more information about this study, including how to volunteer, contact Joseph Lim

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

    • Last Updated
      07/23/2024
    • Study HIC
      #2000027577